Rawa K. Ismail - Concepedia

Author

Rawa K. Ismail

Dutch Institute for Clinical Auditing ORCID

Also Known As

Ismail Rahman, Ismail, Rawa Kamaran, R. Ismail, R. K. Ismail, R.K. Ismail, Rawa Ismail, Rawa K. Ismail, Rawa Kamaran Ismail, Rhorfi Abderrahman Ismail, Rida Ismail

Publications

316

Citations

H-Index

Concepts

All Affiliations

Dutch Institute for Clinical Auditing The Netherlands Cancer Institute University Medical Center Groningen Radboud University Medical Center Amphia Ziekenhuis

About

Rawa K. Ismail is an author at Dutch Institute for Clinical Auditing specializing in cancer research, oncology, and neuro-oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	36
2	Health Sciences	1	1	10
3	Health Policy	1	1	10
4	Pathology	1	1	26
5	Cancer Epidemiology	1	1	10

Rawa K. Ismail

Publications

289

Citations

H-Index

Page 1

	Year	Citations
Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study Olivier J. van Not, Melissa M. de Meza, Alfons J.M. van den Eertwegh, European Journal of Cancer	2022	56
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer Rawa K. Ismail, Jesper van Breeschoten, Michel W.J.M. Wouters, The Breast	2021	40
Real‐world outcomes of advanced melanoma patients not represented in phase <scp>III</scp> trials Michiel C.T. van Zeijl, Rawa K. Ismail, Liesbeth C. de Wreede, International Journal of Cancer	2020	36
The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients Rawa K. Ismail, Franz M.N.H. Schramel, Maaike van Dartel, Lung Cancer	2020	36
Adjuvant treatment for melanoma in clinical practice – Trial versus reality Melissa M. de Meza, Rawa K. Ismail, Daan Jan Willem Rauwerdink, European Journal of Cancer	2021	32
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors Rawa K. Ismail, Karijn P.M. Suijkerbuijk, Anthonius de Boer, Melanoma Research Neuro-oncologyReal-world PatientsMedicineBraf-mek InhibitorsMelanoma	2022	26
The unfavorable effects of <scp>COVID</scp>‐19 on Dutch advanced melanoma care Olivier J. van Not, Jesper van Breeschoten, Alfonsus Johannes Maria van den Eertwegh, International Journal of Cancer	2021	22
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021 Olivier J. van Not, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, EClinicalMedicine	2024	20
Real-world outcomes of advanced melanoma patients not represented in phase III trials. Rawa K. Ismail, M van Zeijl, Liesbeth C. de Wreede, Journal of Clinical Oncology	2020	11
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases Rawa K. Ismail, Nienke O. Sikkes, Michel W.J.M. Wouters, Melanoma Research Cancer ManagementCancer RegistrationPharmacotherapyNeuro-oncologyOncology	2020	10

Page 1